Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval

Erick H. Turner

doi:10.1016/S2215-0366(19)30394-3

Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval

Erick H. Turner

Psychiatry

Research output: Contribution to journal › Comment/debate › peer-review

110 Scopus citations

Original language	English (US)
Pages (from-to)	977-979
Number of pages	3
Journal	The Lancet Psychiatry
Volume	6
Issue number	12
DOIs	https://doi.org/10.1016/S2215-0366(19)30394-3
State	Published - Dec 2019

ASJC Scopus subject areas

Psychiatry and Mental health
Biological Psychiatry

Access to Document

10.1016/S2215-0366(19)30394-3

Cite this

@article{0fc250a0111243e8915379d72b78a50c,

title = "Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval",

author = "Turner, {Erick H.}",

year = "2019",

month = dec,

doi = "10.1016/S2215-0366(19)30394-3",

language = "English (US)",

volume = "6",

pages = "977--979",

journal = "The Lancet Psychiatry",

issn = "2215-0366",

publisher = "Elsevier Limited",

number = "12",

}

TY - JOUR

T1 - Esketamine for treatment-resistant depression

T2 - seven concerns about efficacy and FDA approval

AU - Turner, Erick H.

PY - 2019/12

Y1 - 2019/12

UR - http://www.scopus.com/inward/record.url?scp=85075164062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075164062&partnerID=8YFLogxK

U2 - 10.1016/S2215-0366(19)30394-3

DO - 10.1016/S2215-0366(19)30394-3

M3 - Comment/debate

C2 - 31680014

AN - SCOPUS:85075164062

SN - 2215-0366

VL - 6

SP - 977

EP - 979

JO - The Lancet Psychiatry

JF - The Lancet Psychiatry

IS - 12

ER -

Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this